Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796884 · ClinicalTrials.gov registry record · Phase 2
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
A Phase 2 study of Stage III Colorectal Cancer AJCC v8 and Colorectal Adenoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Active
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 3
- Study locations
NCT03796884: Active Phase 2 study of Stage III Colorectal Cancer AJCC v8 and Colorectal Adenoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
NCT03796884 is a Phase 2 study of Stage III Colorectal Cancer AJCC v8 and Colorectal Adenoma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 230 participants, above the 115-participant average among 17 other Stage III Colorectal Cancer AJCC v8 trials with a reported enrollment target (100% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03796884, a Phase 2 study of Stage III Colorectal Cancer AJCC v8 and Colorectal Adenoma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies the how well linaclotide works in treating patients with stages 0-3 colorectal cancer. Linaclotide is a very small protein that binds to receptors on intestinal cells and makes them secrete water and salt.
Primary Outcome
Will compare cGMP levels in adenomas between study arms using a two-sample t-test (alpha=.05; two-sided) or Wilcoxon rank sum test.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Linaclotide
Study Locations (3)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Washington
- VA Puget Sound Health Care Sysem - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03796884 still lists
NCT03796884 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 17 other Stage III Colorectal Cancer AJCC v8 trials with a reported enrollment target (100% higher).
The record links to 10 conditions, with Stage III Colorectal Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03796884 reports a single indexed study location in Pennsylvania, Washington.
Frequently Asked Questions
What is clinical trial NCT03796884 about?
NCT03796884 is a clinical study titled "Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer". This phase II trial studies the how well linaclotide works in treating patients with stages 0-3 colorectal cancer. Linaclotide is a very small protein that binds to receptors on intestinal cells and makes them secrete water and salt.
What is the current status of trial NCT03796884?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2019-10-30. Estimated completion is 2026-06-30.
What conditions does trial NCT03796884 study?
This clinical trial studies the following conditions: Stage III Colorectal Cancer AJCC v8, Colorectal Adenoma, Stage II Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8.
What interventions are being tested in trial NCT03796884?
The interventions under investigation include: Placebo (OTHER), Linaclotide (DRUG).
Who is sponsoring clinical trial NCT03796884?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03796884 being conducted?
This trial has 3 study locations across Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Colorectal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03796884's enrollment target sits among peer trials
230 2nd of 17 the highest of 17 other Stage III Colorectal Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Colorectal Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI